AccurKardia vs Biobeat (2026)
Two cardiac and vital sign products that differ on whether the data already exists. AccurKardia interprets the electrocardiogram: its cleared Class II software gives beat by beat single lead analysis and rhythm classification, deliberately device agnostic across sources, though the company's filings describe signal processing and a proprietary algorithm rather than a trained model, and the site shows sources such as mobile cardiac telemetry that the cleared indication does not reach. Biobeat creates the data instead, putting wearable monitors on patients who are otherwise checked every few hours, with clearances for cuffless measurement; its early warning score is described in the company's own paper as expert defined rules, and no clearance covers it. The dividing line is whether your failure is interpretation capacity or observation frequency. Both call their products AI, and for both the published method describes something else, so ask each what is learned and what is fixed.
- It analyzes the electrocardiogram itself, cleared Class II software giving beat by beat single lead interpretation across 13 rhythm classifications, deliberately device agnostic across ECG sources.
- The input is a tracing the health system already captures, so the constraint it addresses is interpretation capacity rather than data collection.
- For an organization with volumes of unread or slowly read tracings, that is the bottleneck and this is aimed at it.
- It changes what data exists, putting wearable monitors on patients who are otherwise checked intermittently, with a progression of clearances for cuffless measurement.
- One platform spans hospital wards, clinics, long term care and the home, the settings its clearance names, and excludes critical care.
- More frequent vital signs reach deterioration that a periodic tracing will not show, because the event happens between checks.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. AccurKardia and Biobeat are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | AccurKardia | Biobeat |
|---|---|---|
| Primary category | Diagnostics & Genomics | Inpatient Deterioration & Risk Monitoring |
| Founded | 2019 | 2016 |
| Headquarters | New York, New York, United States | Petah Tikva, Israel |
| Website | accurkardia.com | bio-beat.com |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
AccurKardia makes AccurECG, cloud based software for automated interpretation of ambulatory ECG recordings, sold to cardiac monitoring companies, device manufacturers, hospitals and independent diagnostic testing facilities.
Source: AI Health Index, September 2026
Biobeat sells wearable vital sign monitors and a cloud platform for hospitals, long term care and home programs. The hardware is a single use chest patch and a wrist worn device built on a reflective photoplethysmography sensor, and from that optical signal the company derives blood pressure without a cuff (after calibration against a cleared cuff), oxygen saturation, pulse rate, respiratory rate, body temperature, stroke volume and cardiac output.
Source: AI Health Index, September 2026
Questions buyers ask
How are AccurKardia and Biobeat priced and sold?
For AccurKardia, the company sells interpretation software to cardiac monitoring companies, device manufacturers, hospitals and independent diagnostic testing facilities, and describes version 2.0 as built to process high volume ECG streams at lower cost; its site links terms of use.
With Biobeat, the chest patch is single use and runs for up to 120 hours per the clearance summary, so cost recurs with every monitored patient and scales with how widely a ward deploys it, alongside the wrist device and the cloud platform; the company also offers ambulatory blood pressure monitoring and home sleep services. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
How do AccurKardia and Biobeat handle patient data?
In AccurKardia's case, the data path crosses several organizations. The platform is cloud based and ingests recordings made on other companies' patches and Holter monitors, returning interpretations to monitoring services, hospitals and diagnostic testing facilities, so one recording can pass through a device maker, a monitoring service, this interpretation layer and a reading facility, each with its own terms.
For Biobeat, the in hospital monitoring page describes a secure, HIPAA and GDPR compliant cloud based patient management system, and the clearance summaries describe the path: patch to a Bluetooth gateway to the cloud to a web application. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
Which settings and specialties do AccurKardia and Biobeat cover?
With AccurKardia, the version 2.0 indication covers adults 22 and older prescribed outpatient cardiac monitoring for up to ten days, single lead recordings from wet silver chloride electrodes, assessed by qualified healthcare professionals in office or clinical settings, across 13 rhythm classifications, which is narrow and supported by FDA review.
In Biobeat's case, the company offers a hospital solution for short term monitoring, a telehealth solution for long term monitoring, and at home services including ambulatory blood pressure monitoring and a home sleep lab, and has described use across wards, step down and post surgical units, long term care and hospital at home. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Remote Monitoring & Chronic Care page.
Neither vendor publishes subgroup or population performance, and the exposure differs by modality in a way buyers should hold: electrocardiogram morphology varies with sex, age and body habitus, while optical vital sign measurement is known to perform differently across skin tones. Ask each for performance stratified accordingly.
Match AccurKardia's cleared indication to the recording source you plan to use, and ask Biobeat how its score's rules were set, since its clearances cover the measurements and not the score. Neither publishes pricing.